IJHOSCR
Original Article
International Journal of Hematology-Oncology and Stem Cell Research
High Prevalence of Vitamin D Deficiency in Newly Diagnosed Acute Myeloid Leukemia Patients and Its Adverse Outcome Fatere Seyedalipour1, Ava Mansouri2, Mohammad Vaezi3, Kheirollah Gholami1,2, Kazem Heidari2, Molouk Hadjibabaie1,2, Ardeshir Ghavamzadeh3 1
Clinical Pharmacy Department, School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran Research Center for Rational Use of Drugs, School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran Hematology-Oncology and Stem Cell Transplantation Research Center, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran 2 3
Corresponding Author: Molouk Hadjibabaie, Research Center for Rational Use of Drugs and Clinical Pharmacy Department, School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran Tel/ Fax: 982188814157 E-mail: [email protected] Received: 23, Nov, 2016 Accepted: 27, Dec, 2016
ABSTRACT Background: Although several studies have supported a preventive and therapeutic role of vitamin D (Vit D) for different types of cancers, we face insufficient documentation in acute myeloid leukemia (AML). So, we examined whether the serum calcidiol (25(OH)D) levels at the time of induction therapy have any impact on response and relapse in AML patients. Materials and Methods: Blood samples were collected from 65 patients on days 0 and 28th of treatment to evaluate serum concentration of 25(OH)D and its effects on complete remission (CR) achievement, relapse rate and hospitalization length. Results: Of the 65 patients who were included in the study, 38 were male (58.5%) and 27 were female (41.5%). Median age at the time of treatment was 37 years (range 15-68). 6% of the participants were older than 60 years. In regard to 25(OH)D levels, 81.5% of AML patients were deficient (levels
Original Article
International Journal of Hematology-Oncology and Stem Cell Research
High Prevalence of Vitamin D Deficiency in Newly Diagnosed Acute Myeloid Leukemia Patients and Its Adverse Outcome Fatere Seyedalipour1, Ava Mansouri2, Mohammad Vaezi3, Kheirollah Gholami1,2, Kazem Heidari2, Molouk Hadjibabaie1,2, Ardeshir Ghavamzadeh3 1
Clinical Pharmacy Department, School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran Research Center for Rational Use of Drugs, School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran Hematology-Oncology and Stem Cell Transplantation Research Center, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran 2 3
Corresponding Author: Molouk Hadjibabaie, Research Center for Rational Use of Drugs and Clinical Pharmacy Department, School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran Tel/ Fax: 982188814157 E-mail: [email protected] Received: 23, Nov, 2016 Accepted: 27, Dec, 2016
ABSTRACT Background: Although several studies have supported a preventive and therapeutic role of vitamin D (Vit D) for different types of cancers, we face insufficient documentation in acute myeloid leukemia (AML). So, we examined whether the serum calcidiol (25(OH)D) levels at the time of induction therapy have any impact on response and relapse in AML patients. Materials and Methods: Blood samples were collected from 65 patients on days 0 and 28th of treatment to evaluate serum concentration of 25(OH)D and its effects on complete remission (CR) achievement, relapse rate and hospitalization length. Results: Of the 65 patients who were included in the study, 38 were male (58.5%) and 27 were female (41.5%). Median age at the time of treatment was 37 years (range 15-68). 6% of the participants were older than 60 years. In regard to 25(OH)D levels, 81.5% of AML patients were deficient (levels
